A PHASE 1/2 STUDY OF MT‐3724 TO EVALUATE SAFETY, PHARMACODYNAMICS AND EFFICACY OF MT‐3724 FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA. (12th June 2019) - Burnett, C.A.; Hamlin, P.; Dabovic, K.; Higgins, J.; Persky, D.O.